TG Therapeutics, Inc. Press Releases

Get TGTX Alerts
*Delayed - data as of Aug. 29, 2014  -  Find a broker to begin trading TGTX now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    TGTX After Hours
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
Basic Chart Interactive Chart
Company Headlines Press Releases Market Stream
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Filtered By
Ordered By

TG Therapeutics Announces Novel "Chemo-free" Triple Therapy Combination Clinical Study for Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies
8/15/2014 7:30:00 AM - GlobeNewswire

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014
8/11/2014 8:00:00 AM - Business Wire

TG Therapeutics' Novel Combination of TG-1101 (Ublituximab) and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas
7/21/2014 4:05:00 PM - GlobeNewswire

TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update
7/21/2014 4:05:00 PM - GlobeNewswire

TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development of Inhibitors of IRAK4
6/24/2014 8:08:00 AM - GlobeNewswire

Ligand Signs Global License Agreement with TG Therapeutics for IRAK-4 Inhibitor Program
6/24/2014 3:01:00 AM - Business Wire

TG Therapeutics, Inc. to Present at the 2014 JMP Securities Healthcare Conference
6/23/2014 8:30:00 AM - GlobeNewswire

TG Therapeutics, Inc. to Present at the 2014 Wells Fargo Healthcare Conference
6/16/2014 4:30:00 PM - GlobeNewswire

TG Therapeutics' TG-1101 (Ublituximab) in Combination With Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
6/13/2014 5:30:00 AM - GlobeNewswire